BVI lance durant le congrès ESCRS 2024 de nouvelles lentilles intraoculaires monofocales premium SERENITY et SERENITY Toric, offrant un champ étendu de vision aux patients. 

Geplaatst op
  • Les lentilles intraoculaires non diffractives SERENITY et SERENITY Toric sont la deuxième génération de la lentille intraoculaire monofocale premium ISOPURE de BVI lancée en 2019. 
  • Ces lentilles intraoculaires utilisent la technologie optique brevetée ISOFOCAL visant à offrir à la fois une vision de loin et une vision intermédiaire.1 La plateforme révolutionnaire POD à double anse en C est spécialement conçue pour offrir une correction de l'astigmatisme et un positionnement stable de la lentille intraoculaire.2 
  • Ces lentilles sont conçues pour répondre à la demande croissante de lentilles intraoculaires à vision intermédiaire, qui devrait connaître un TCAC de 15 %.3 

Waltham, MA, 3 Septembre 2024 – BVI a dévoilé aujourd'hui ses dernières innovations: les lentilles intraoculaires monofocales premium SERENITY et SERENITY Toric. Ces lentilles intraoculaires asphériques non diffractives constituent la deuxième génération de la gamme pionnière ISOPURE de BVI, introduite pour la première fois en 2019. Utilisant la technologie optique brevetée ISOFOCAL pour équilibrer élégamment la profondeur de champ (DoF) et la qualité de l'image, ces lentilles offrent une vision de loin égale à une lentille monofocale en ajoutant une bonne vision intermédiaire jusqu'à 66 cm.1  Lees verder

BVI Expands IOL Capacity with New State of the Art Facility in Belgium

Geplaatst op

WALTHAM, Mass. — July 18th, 2023 (GLOBE NEWSWIRE) — BVI, one of the fastest growing surgical ophthalmic businesses in the world, is proud to announce the opening of its new, state of the art facility in Liège, Belgium.  This results in a sizeable increase in BVI’s intraocular lens (IOL) business capacity, unlocking new growth opportunities and reinforcing the company’s environmental, social, and governance (ESG) leadership. Lees verder

BVI Announces Certification for its Intraocular Lens Portfolio under the European Medical Device Regulation

Geplaatst op

WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- BVI, a diversified global ophthalmic device company, today announced certification for its intraocular lens (IOL) portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medical Device Directive (MDD). Lees verder

BVI acquires Benz Research & Development, strengthening end to end IOL design, production and sales capabilities

Geplaatst op
  • Benz R&D is the leading technologically advanced independent supplier of performance materials and manufacturing technology to the IOL industry
  • BVI’s vertical integration will accelerate manufacturing capacity and geographic sales expansion, and the IOL material capabilities of BVI’s world leading PhysIOL® lens platform

Waltham, MA – October 15, 2020  Lees verder

Gold | Professional Sales Tool, 2020

Geplaatst op

BVI and Merge 

CustomEyes Configurator

With 1,400 products sold in markets around the world, BVI was struggling with a convoluted sales process. Sales reps were frustrated with antiquated procedures, including a physical catalog to find and enter SKUs into a spreadsheet, emailing orders to support teams for verification and building the sample pack.  Continue reading the article today! Lees verder

BVI expands Malosa single-use instrument range in the US

Geplaatst op
  •  BVI broadens its widely popular range of Malosa® single-use ophthalmic instruments to
    span cataract, oculoplastic, corneal refractive procedures and other office-based
    procedures.
  • Malosa single-use instruments help surgeons focus on precision, reduce cross
    contaminations, and increase operating room efficiency.

Waltham, MA – September 8, 2020 – BVI, the fastest growing diversified company in
ophthalmology, today announced the extension of its Malosa®
range of single-use ophthalmic
instruments in the US. The US Malosa portfolio will now include specialty instruments for use in
corneal refractive surgery, complementing the existing single-use product range for cataract,
oculoplastic and office-based procedures, such as LASIK, PRK and SMILE®. Lees verder